Tyra Biosciences, Inc. (NASDAQ:TYRA)
| Market Cap | $1.39B-9.6% |
| Revenue (ttm) | n/a |
| Net Income | n/a-52.1% |
| EPS | n/a-41.2% |
| Shares Out | 68.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 467,578 |
| Open | $19.62 |
| Previous Close | $19.73 |
| Day's Range | $19.62 - $20.44 |
| 52-Week Range | $18.25 - $40.65 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | $43.40(+115.71%) |
| Earnings Date | n/a |
About TYRA
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Tyra Biosciences, Inc. Stock Analysis — InsiderScore
Tyra Biosciences, Inc. scored higher than 8% of companies evaluated by InsiderBuying, and ranked 84th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Tyra Biosciences, Inc. bought $20.0K of stock across 1 purchase in the last 90 days, the largest of them $20.0K.
None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating TYRA in the last 3 months, one vote each. Issuer-paid research is not counted.
$TYRA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TYRA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TYRA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TYRA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TYRA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TYRA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TYRA
| XBIState Street SPDR S&P Biotech ETF | $23.35M |
| VTIVanguard Morningstar Total Stock Market ETF | $20.46M |
| IWMiShares Russell 2000 ETF | $18.94M |
| VXFVanguard Extended Market ETF | $10.54M |
| IBBiShares Biotechnology ETF | $8.11M |
| IWOiShares Russell 2000 Growth ETF | $6.93M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TYRA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mixed coverage with positive Phase 2 trial data offset by widening Q3 net losses; financial headwinds weigh on early-stage clinical progress.
Recent Insider Activity
Insider Score Trend Over Time
+4.6 since Sep 16Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| SBIO | ALPS Medical Breakthroughs ETF | 0.77% |
| TDNA | T. Rowe Price Biotech ETF | 0.62% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.57% |
| CANC | Tema Oncology ETF | 0.28% |
| XBI | State Street SPDR S&P Biotech ETF | 0.23% |
| PJSM | PGIM Jennison Small-Mid Cap Core Equity ETF | 0.21% |
| ESSC | Eventide Small Cap ETF | 0.15% |
| OPTZ | Optimize Strategy Index ETF | 0.13% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.08% |
| IBB | iShares Biotechnology ETF | 0.07% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.06% |
| TMSL | T. Rowe Price Small-Mid Cap ETF | 0.05% |
Weight is the stock’s share of each fund’s holdings.
